ConvaTec Group

ConvaTec Group

ConvaTec originated within E.R. Squibb & Sons in 1978 and operated as a division of Bristol-Myers Squibb until it was spun out in a 2008 carve-out led by private equity firms Nordic Capital and Avista Capital Partners. The company has since evolved into a standalone public entity, listed on the London Stock Exchange under the ticker CTEC, with a global operational footprint spanning the United States, Europe, and emerging markets. Its founding product category — ostomy care for patients with surgical stomas — remains a core revenue driver alongside chronic wound management and continence care. The company's strategy rests on direct manufacturing and distribution of single-use medical devices and consumables within four franchises: Advanced Wound Care, Ostomy Care, Continence & Critical Care, and Infusion Care. Unlike allocators that deploy capital into third-party funds, ConvaTec invests in production lines, clinical evidence generation, and regulatory approvals. Notable market positions include its DuoDERM and AQUACEL wound dressings, which compete with offerings from Smith & Nephew and 3M, and its GentleCath intermittent catheters. Revenue is geographically diversified, with North America typically generating the largest share, followed by Europe and rest-of-world markets including Asia-Pacific and Latin America. ConvaTec employs roughly 10,000 people worldwide, operating manufacturing and R&D facilities in countries including the Dominican Republic, Slovakia, and the United Kingdom. CEO Karim Bitar, who took the role in September 2019, has focused on a turnaround strategy branded as 'FISBE' (Focus-Innovate-Simplify-Build-Execute), targeting mid-single-digit organic revenue growth and margin expansion. In November 2023, the company announced the appointment of a new Chief Financial Officer, Jonny Mason, as part of ongoing executive leadership refreshment (per company press release, November 2023). The firm also maintains partnerships with clinical organizations and patient advocacy groups to strengthen category leadership. What structurally separates ConvaTec is its position as a pure-play chronic-care consumables manufacturer entirely dependent on reimbursement codes, clinician prescribing habits, and hospital group purchasing contracts — not investment allocations. The company faces a distinct governance challenge in managing a heavily regulated medical-device supply chain across multiple FDA and EU MDR jurisdictions, with manufacturing concentration in lower-cost regions. Its succession and R&D pipeline decisions are governed by a public board and tested quarterly in earnings calls, creating a transparency posture unusual for privately held industrial companies but standard for a FTSE 250 constituent.